AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
Log in

NASDAQ:XENEXenon Pharmaceuticals Stock Price, Forecast & News

$13.38
-0.40 (-2.90 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$12.50
Now: $13.38
$13.86
50-Day Range
$10.56
MA: $13.00
$14.90
52-Week Range
$7.00
Now: $13.38
$18.45
Volume149,247 shs
Average Volume265,079 shs
Market Capitalization$467.95 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Xenon Pharmaceuticals, Inc. engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P. Kastelein, and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.
Read More
Xenon Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.57 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XENE
CUSIPN/A
Phone604-484-3300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$6.83 million
Book Value$2.99 per share

Profitability

Net Income$-41,600,000.00

Miscellaneous

Employees89
Market Cap$467.95 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive XENE News and Ratings via Email

Sign-up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter.

Xenon Pharmaceuticals (NASDAQ:XENE) Frequently Asked Questions

How has Xenon Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Xenon Pharmaceuticals' stock was trading at $12.71 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, XENE shares have increased by 5.3% and is now trading at $13.38. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Xenon Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Xenon Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Xenon Pharmaceuticals.

When is Xenon Pharmaceuticals' next earnings date?

Xenon Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Xenon Pharmaceuticals.

How were Xenon Pharmaceuticals' earnings last quarter?

Xenon Pharmaceuticals Inc (NASDAQ:XENE) posted its earnings results on Thursday, May, 21st. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.32) by $0.10. The biopharmaceutical company had revenue of $7.08 million for the quarter, compared to analysts' expectations of $7.50 million. View Xenon Pharmaceuticals' earnings history.

What price target have analysts set for XENE?

3 analysts have issued 1-year price objectives for Xenon Pharmaceuticals' shares. Their forecasts range from $23.00 to $25.00. On average, they anticipate Xenon Pharmaceuticals' share price to reach $24.00 in the next year. This suggests a possible upside of 79.4% from the stock's current price. View analysts' price targets for Xenon Pharmaceuticals.

Has Xenon Pharmaceuticals been receiving favorable news coverage?

News stories about XENE stock have trended somewhat positive on Wednesday, according to InfoTrie. The research group ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Xenon Pharmaceuticals earned a news impact score of 1.8 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutXenon Pharmaceuticals.

Who are some of Xenon Pharmaceuticals' key competitors?

What other stocks do shareholders of Xenon Pharmaceuticals own?

Who are Xenon Pharmaceuticals' key executives?

Xenon Pharmaceuticals' management team includes the following people:
  • Simon Neil Pimstone, Chief Executive Officer & Director
  • Ian C. Mortimer, President, Chief Financial Officer & Secretary
  • Ernesto Aycardi, Chief Medical Officer
  • Robin Sherrington, Executive VP-Business & Corporate Development
  • Charles J. Cohen, Vice President-Biological Sciences

What is Xenon Pharmaceuticals' stock symbol?

Xenon Pharmaceuticals trades on the NASDAQ under the ticker symbol "XENE."

Who are Xenon Pharmaceuticals' major shareholders?

Xenon Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (4.76%), Bank of New York Mellon Corp (1.93%), Rock Springs Capital Management LP (1.43%), Driehaus Capital Management LLC (1.32%), Ikarian Capital LLC (1.27%) and Vivo Capital LLC (1.13%). Company insiders that own Xenon Pharmaceuticals stock include Frank A Holler, Mohammad Azab and Simon N Pimstone. View institutional ownership trends for Xenon Pharmaceuticals.

Which institutional investors are selling Xenon Pharmaceuticals stock?

XENE stock was sold by a variety of institutional investors in the last quarter, including Soleus Capital Management L.P., Squarepoint Ops LLC, JPMorgan Chase & Co., Falcon Point Capital LLC, and State Street Corp. Company insiders that have sold Xenon Pharmaceuticals company stock in the last year include Frank A Holler, Mohammad Azab, and Simon N Pimstone. View insider buying and selling activity for Xenon Pharmaceuticals.

Which institutional investors are buying Xenon Pharmaceuticals stock?

XENE stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Rock Springs Capital Management LP, Driehaus Capital Management LLC, Bank of New York Mellon Corp, Vivo Capital LLC, Ghost Tree Capital LLC, Ikarian Capital LLC, and Burrage Capital Management LLC. View insider buying and selling activity for Xenon Pharmaceuticals.

How do I buy shares of Xenon Pharmaceuticals?

Shares of XENE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Xenon Pharmaceuticals' stock price today?

One share of XENE stock can currently be purchased for approximately $13.38.

How big of a company is Xenon Pharmaceuticals?

Xenon Pharmaceuticals has a market capitalization of $467.95 million and generates $6.83 million in revenue each year. The biopharmaceutical company earns $-41,600,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Xenon Pharmaceuticals employs 89 workers across the globe.

What is Xenon Pharmaceuticals' official website?

The official website for Xenon Pharmaceuticals is www.xenon-pharma.com.

How can I contact Xenon Pharmaceuticals?

Xenon Pharmaceuticals' mailing address is 200 - 3650 GILMORE WAY, BURNABY A1, V5G 48W. The biopharmaceutical company can be reached via phone at 604-484-3300 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.